Immunotherapies, especially PD‐1/PD‐L1 and CTLA‐4 blockade, have revolutionized the treatment paradigm for non‐small cell lung cancer (NSCLC) and become the standard treatment for the early and advanced stages of NSCLC without driving oncogenic mutation.1, 2, 3, 4, 5, 6, 7. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.